Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Derk Purcell"'
Autor:
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/235d44fcb4a64fba89f8c186629bc9ac
Autor:
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-12 (2024)
Abstract Background Alzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and families globally. Lecanemab, an FDA-approved amyloid beta (Aβ)-directed antibody indicated for the treatment
Externí odkaz:
https://doaj.org/article/37323811cfca4e539a625fdbaee2b067
Autor:
Luc Bracoud, Gregory Klein, Marco Lyons, Marzia A. Scelsi, Jakub Wojtowicz, Szofia Bullain, Derk Purcell, Jochen B. Fiebach, Jerome Barakos, Joyce Suhy
Publikováno v:
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 15, Iss 4, Pp n/a-n/a (2023)
Abstract INTRODUCTION Anti‐amyloid‐β (Aβ) monoclonal antibodies (mAbs) offer the promise of disease modification and are emerging treatment options in Alzheimer's disease. Anti‐Aβ mAbs require brain magnetic resonance imaging (MRI) examinati
Externí odkaz:
https://doaj.org/article/0a57cfd7b6f540439a1f6617d797b642
Autor:
Gregory Klein, Marzia A. Scelsi, Jerome Barakos, Jochen B. Fiebach, Luc Bracoud, Joyce Suhy, Paul Delmar, Marco Lyons, Jakub Wojtowicz, Szofia Bullain, Frederik Barkhof, Derk Purcell
Publikováno v:
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 14(1):e12376. Elsevier BV
Klein, G, Scelsi, M A, Barakos, J, Fiebach, J B, Bracoud, L, Suhy, J, Delmar, P, Lyons, M, Wojtowicz, J, Bullain, S, Barkhof, F & Purcell, D 2022, ' Comparing ARIA-E severity scales and effects of treatment management thresholds ', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 14, no. 1, e12376 . https://doi.org/10.1002/dad2.12376
Klein, G, Scelsi, M A, Barakos, J, Fiebach, J B, Bracoud, L, Suhy, J, Delmar, P, Lyons, M, Wojtowicz, J, Bullain, S, Barkhof, F & Purcell, D 2022, ' Comparing ARIA-E severity scales and effects of treatment management thresholds ', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 14, no. 1, e12376 . https://doi.org/10.1002/dad2.12376
Introduction: Amyloid-related imaging abnormalities–edema (ARIA-E) is associated with anti-amyloid beta monoclonal antibody treatment. ARIA-E severity may be assessed using the Barkhof Grand Total Scale (BGTS) or the 3- or 5-point Severity Scales o
Autor:
Derk Purcell
Publikováno v:
Laryngoscope; Aug2006, Vol. 116 Issue 8, p1439-1446, 8p